Société des Industries Pharmaceutiques de Tunisie - Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Société des Industries Pharmaceutiques de Tunisie -'s performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2020 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Société des Industries Pharmaceutiques de Tunisie - makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 20 | 20 | -17 | 19 | 0 |
| 31 Mar 20 | 22 | -16 | 18 | 0 |
| 31 Dec 19 | 24 | -15 | 18 | 0 |
| 30 Jun 19 | 29 | -17 | 19 | 0 |
| 31 Mar 19 | 31 | -15 | 19 | 0 |
| 31 Dec 18 | 33 | -14 | 18 | 0 |
| 30 Sep 18 | 36 | -11 | 18 | 0 |
| 30 Jun 18 | 38 | -8 | 18 | 0 |
| 31 Mar 18 | 38 | -8 | 18 | 0 |
| 31 Dec 17 | 37 | -8 | 18 | 0 |
| 30 Sep 17 | 39 | -7 | 19 | 0 |
| 30 Jun 17 | 40 | -6 | 19 | 0 |
| 31 Mar 17 | 41 | -5 | 19 | 0 |
| 31 Dec 16 | 43 | -4 | 20 | 0 |
| 30 Sep 16 | 42 | -4 | 20 | 0 |
| 30 Jun 16 | 42 | -4 | 20 | 0 |
| 31 Mar 16 | 43 | -4 | 20 | 0 |
| 31 Dec 15 | 45 | -3 | 20 | 0 |
| 30 Sep 15 | 44 | -4 | 20 | 0 |
| 30 Jun 15 | 43 | -5 | 20 | 0 |
| 31 Mar 15 | 42 | -6 | 20 | 0 |
| 31 Dec 14 | 41 | -7 | 20 | 0 |
| 30 Sep 14 | 41 | -6 | 20 | 0 |
| 30 Jun 14 | 41 | -5 | 21 | 0 |
| 31 Mar 14 | 43 | -3 | 21 | 0 |
| 31 Dec 13 | 45 | -1 | 20 | 0 |
| 30 Sep 13 | 47 | -1 | 20 | 0 |
| 30 Jun 13 | 48 | 0 | 20 | 0 |
Quality Earnings: Insufficient data to determine if SIPHA has high quality earnings.
Growing Profit Margin: Insufficient data to determine if SIPHA's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if SIPHA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare SIPHA's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if SIPHA's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: SIPHA has a negative Return on Equity (0%), as it is currently unprofitable.